mechlorethamine


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

mechlorethamine

 [mek″lor-eth´ah-mēn]
an alkylating agent that produces interstrand and intrastrand cross-linkages in DNA with resultant miscoding, breakage, and failure of replication. Used primarily for the treatment of disseminated hodgkin's disease, especially in the MOPP treatment regimen, and for other lymphomas, including mycosis fungoides; administered intravenously as the hydrochloride salt. Called also nitrogen mustard.

mechlorethamine

/mech·lor·eth·amine/ (mek″lor-eth´ah-mēn) one of the nitrogen mustards, used in the form of the hydrochloride salt as an antineoplastic, particularly in disseminated Hodgkin's disease.

mechlorethamine

A nitrogen mustard derivative which binds to DNA, crosslinking both strands to prevent its replication.

Global village
Mechlorethamine was first developed as a chemical weapon.

Oncology
A nitrogen mustard alkylating agent used for managing lymphomas; part of MOPP.
 
Adverse effects
Nausea, vomiting, marrow suppression, skin vesiculation at injection site.

mechlorethamine

Oncology An alkylating nitrogen mustard chemotherapeutic used for lymphomas Adverse effects GI Sx, BM suppression, skin vesiculation at injection site. See MOPP regimen.

ni·tro·gen mus·tards

(HN) (nī'trŏ-jĕn mŭs'tărdz)
A group of toxic chemicals developed for use as chemical-warfare agents.

mechlorethamine

References in periodicals archive ?
Topical mechlorethamine preparations are currently recommended as first line-treatment for early stage CTCL by the National Comprehensive Cancer Network (NCCN); however, there are no FDA-approved topical mechlorethamine products, limiting availability to non-standardized, pharmacy-compounded preparations.
The basis for the approval came from the positive results from a randomised, observer-blinded, non-inferiority pivotal trial that compared Valchlor to a pharmacycompounded mechlorethamine preparation in patients with stage IA-IIA MF-type CTCL.
The firm is seeking US approval of its mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, the most common type of Cutaneous T-Cell Lymphoma (CTCL).
Prior to the financing, Ceptaris received a Complete Response Letter from the Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL).
The funding will be used for ongoing operational expenses and preparation for commercialization of its investigational drug, mechlorethamine gel.
The EMA's decision to grant Orphan Drug Designation to our proprietary mechlorethamine gel underscores the need for additional therapeutic alternatives for patients with Cutaneous T-Cell Lymphoma," said Ceptaris Chairman of the Board and CEO Steve Tullman.
The new drug application (NDA) for Ceptaris' mechlorethamine gel was filed in July 2011.
Currently, topical mechlorethamine preparations are recommended for treatment of early stage CTCL by the National Comprehensive Cancer Network (NCCN).
The treatment for Hodgkin lymphoma is dominated by the combination of generic drugs like doxorubicin, bleomycin, vinblastine, dacarbazine, mechlorethamine, etoposide, vincristine, prednisone, cyclophosphamide, procarbazine, chlorambucil, methylprednisolone, cytarabine, cisplatin and dexamethasone.
Yaupon recently submitted a New Drug Application (NDA) to the FDA for a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, the most common type of cutaneous T-cell lymphoma (CTCL).
Food and Drug Administration (FDA) for its propriety gel formulation of mechlorethamine hydrochloride (mechlorethamine).